Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Frank Martin Sacks, M.D.

Co-Author

This page shows the publications co-authored by Frank Sacks and Marc Pfeffer.
Connection Strength

1.349
  1. Leapfrogging data: no shortcuts for safety or efficacy information. Circulation. 2008 Dec 09; 118(24):2491-4.
    View in: PubMed
    Score: 0.396
  2. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29; 51(4):435-43.
    View in: PubMed
    Score: 0.093
  3. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation. 2002 May 21; 105(20):2341-6.
    View in: PubMed
    Score: 0.063
  4. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002 Mar 26; 105(12):1424-8.
    View in: PubMed
    Score: 0.062
  5. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. Circ Genom Precis Med. 2021 04; 14(2):e003219.
    View in: PubMed
    Score: 0.058
  6. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000 Oct 17; 102(16):1886-92.
    View in: PubMed
    Score: 0.056
  7. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. J Am Coll Cardiol. 1999 Jan; 33(1):125-30.
    View in: PubMed
    Score: 0.050
  8. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998 Apr 21; 97(15):1446-52.
    View in: PubMed
    Score: 0.047
  9. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 03; 335(14):1001-9.
    View in: PubMed
    Score: 0.043
  10. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol. 1995 Sep 28; 76(9):98C-106C.
    View in: PubMed
    Score: 0.040
  11. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol. 1995 Mar 15; 75(8):621-3.
    View in: PubMed
    Score: 0.038
  12. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) Am J Cardiol. 1991 Dec 01; 68(15):1436-46.
    View in: PubMed
    Score: 0.030
  13. HMG CoA reduction in patients with average cholesterol concentrations. Clin Chem. 2011 Jul; 57(7):1072-3.
    View in: PubMed
    Score: 0.029
  14. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009 Nov 03; 120(18):1784-92.
    View in: PubMed
    Score: 0.026
  15. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):562-7.
    View in: PubMed
    Score: 0.023
  16. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation. 2008 Jan 15; 117(2):163-168.
    View in: PubMed
    Score: 0.023
  17. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006 Jun 17; 332(7555):1426.
    View in: PubMed
    Score: 0.021
  18. Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens. 2006 Aug; 20(8):560-5.
    View in: PubMed
    Score: 0.021
  19. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005 Dec; 16(12):3748-54.
    View in: PubMed
    Score: 0.020
  20. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005 Oct 25; 112(17):2627-33.
    View in: PubMed
    Score: 0.020
  21. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005 Jul 12; 112(2):171-8.
    View in: PubMed
    Score: 0.019
  22. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005 Jul; 68(1):237-45.
    View in: PubMed
    Score: 0.019
  23. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004 Sep 21; 110(12):1557-63.
    View in: PubMed
    Score: 0.018
  24. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003 Oct 15; 42(8):1446-53.
    View in: PubMed
    Score: 0.017
  25. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001 Aug 15; 88(4):347-52.
    View in: PubMed
    Score: 0.015
  26. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000 May 09; 101(18):2149-53.
    View in: PubMed
    Score: 0.014
  27. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999 Jul 20; 100(3):230-5.
    View in: PubMed
    Score: 0.013
  28. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol. 1999 Jul; 34(1):106-12.
    View in: PubMed
    Score: 0.013
  29. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999 Jan 19; 99(2):216-23.
    View in: PubMed
    Score: 0.012
  30. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998 Dec 08; 98(23):2513-9.
    View in: PubMed
    Score: 0.012
  31. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998 Nov 01; 129(9):681-9.
    View in: PubMed
    Score: 0.012
  32. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998 Sep 01; 98(9):839-44.
    View in: PubMed
    Score: 0.012
  33. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998 Jul; 32(1):140-6.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.